

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

IMR-32

RRID:CVCL_0346

Type: Cell Line

Proper Citation

JCRB Cat# IFO50283, RRID:CVCL_0346

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0346

Proper Citation: JCRB Cat# IFO50283, RRID:CVCL_0346

Description: Cell line IMR-32 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:62055](#), [PMID:71759](#), [PMID:327080](#), [PMID:833871](#), [PMID:856461](#), [PMID:922665](#), [PMID:2535691](#), [PMID:3518877](#), [PMID:3698005](#), [PMID:5459762](#), [PMID:6401685](#), [PMID:6888561](#), [PMID:6935474](#), [PMID:7037175](#), [PMID:7139592](#), [PMID:7253718](#), [PMID:7459858](#), [PMID:7838528](#), [PMID:8221663](#), [PMID:8490657](#), [PMID:8665486](#), [PMID:9201287](#), [PMID:9283597](#), [PMID:9516836](#), [PMID:11550280](#), [PMID:11668190](#), [PMID:12210830](#), [PMID:12702577](#), [PMID:15390183](#), [PMID:15892104](#), [PMID:16524757](#), [PMID:16822308](#), [PMID:17974978](#), [PMID:20655465](#), [PMID:22213050](#), [PMID:22460905](#), [PMID:24466371](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:28350380](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31581737](#), [PMID:33460449](#)

Comments: Characteristics: Neuroblastic type (N-type)., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: IMR-32

Synonyms: IMR 32, IMR32, Institute for Medical Research-32, GM03320, GM3320C, GM03320D, AG03320, AG3320

Cross References: BTO:BTO_0000934, CLO:CLO_0006948, CLO:CLO_0016777, EFO:EFO_0001195, MCCL:MCC:0000242, CLDB:cl2878, CLDB:cl2879, CLDB:cl2880, CLDB:cl2881, CLDB:cl2882, CLDB:cl2883, CLDB:cl2885, CLDB:cl2886, CLDB:cl2887, CLDB:cl2888, ABM:T8975, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CCL-127, BCRC:60014, BCRJ:0377, BioGRID_ORCS_Cell_line:637, BioSample:SAMN00808348, BioSample:SAMN03472412, BioSample:SAMN03473082, BioSample:SAMN10988103, cancercellines:CVCL_0346, CCRID:1101HUM-PUMC000282, CCRID:3101HUMTCHu145, CCRID:4201HUM-CCTCC00107, CCTCC:GDC0107, Cell_Model_Passport:SIDM00226, CGH-DB:78-1, CGH-DB:9095-4, ChEMBL-Cells:ChEMBL3307656, ChEMBL-Targets:ChEMBL614585, CLS:300148, Coriell:AG03320, Coriell:GM03320, Cosmic:688067, Cosmic:759892, Cosmic:801746, Cosmic:920239, Cosmic:922658, Cosmic:947702, Cosmic:1019944, Cosmic:1037352, Cosmic:1099149, Cosmic:1109111, Cosmic:1237544, Cosmic:1518066, Cosmic:1526626, Cosmic:2058113, Cosmic:2131590, Cosmic:2301580, Cosmic:2393630, Cosmic:2485944, DepMap:ACH-000310, DSMZ:ACC-165, DSMZCellDive:ACC-165, ECACC:86041809, EGA:EGAS00001000610, GEO:GSM453632, GEO:GSM563362, GEO:GSM692859, GEO:GSM887162, GEO:GSM888234, GEO:GSM1366406, GEO:GSM1669934, GEO:GSM2371237, GEO:GSM2394364, IARC_TP53:23585, ICLC:HTL96021, IZSLER:BS TCL 29, JCRB:IFO50283, JCRB:JCRB9050, KCB:KCB 2011100YJ, KCLB:10127, LiGeA:CCLE_016, LINC_S_LDP:LCL-1965, Lonza:971, PharmacDB:IMR32_659_2019, PRIDE:PXD000589, Progenetix:CVCL_0346, PubChem_Cell_line:CVCL_0346, RCB:RCB1895, TKG:TKG 0207, Wikidata:Q54897618

ID: CVCL_0346

Vendor: JCRB

Catalog Number: IFO50283

Record Creation Time: 20220427T220634+0000

Record Last Update: 20260905T180840+0000

Ratings and Alerts

No rating or validation information has been found for IMR-32.

Warning: Discontinued: RCB; RCB1895

Characteristics: Neuroblastic type (N-type)., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Warning: Discontinued: Coriell; AG03320

Characteristics: Neuroblastic type (N-type)., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 353 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kumar A, et al. (2026) Structure-Guided Synthetic Peptide Targeting Nucleolus and Neural Progenitor Protein Nuclear Import Impairs Ribosome Biogenesis and Cancer Cell Proliferation. *Chembiochem : a European journal of chemical biology*, 27(3), e202500799.

Wang Y, et al. (2026) Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. *Molecular cancer therapeutics*, 25(6), 881.

Lou E, et al. (2026) Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation. *Neuro-oncology*, 28(5), 1335.

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. *iScience*, 29(7), 116469.

Manna S, et al. (2026) KIF5A upregulation by FAK-mediated downregulation of epigenetic modifiers promotes mitochondrial dynamics in neuronal differentiation. *FEBS letters*, 600(1), 63.

Wong CH, et al. (2026) Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma. *Cytotherapy*, 28(7), 102885.

Norouzi M, et al. (2026) DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. *Cancer letters*, 646, 218383.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. *Cancers*, 18(3).

Di Lascio S, et al. (2026) Regulation of PHOX2B gene expression by the long non-coding natural antisense RNA PHOX2B-AS1. *The FEBS journal*, 293(12), 3502.

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. *Molecular cancer therapeutics*, 25(4), 635.

Jungwirth J, et al. (2026) The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e23697.

Chukkapalli S, et al. (2025) POLQ mediated end-joining promotes DNA damage tolerance in neuroblastoma. *Translational oncology*, 58, 102433.

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *Cell chemical biology*, 32(8), 1042.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral CD8⁺T-cell Activity. *Cancer research*, 85(2), 277.

Sharda S, et al. (2025) Mangiferin modulates lipid metabolism via AKR1B1 in response to advanced glycation end products. *British journal of pharmacology*.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Zhang H, et al. (2025) Molecular Characterization of Cancer Preventive and Therapeutic Potential of Three Antistress Compounds, Triethylene Glycol, Withanone, and Withaferin A. *International journal of molecular sciences*, 26(2).

Treis D, et al. (2025) Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. *Cell death & disease*, 16(1), 318.

Pai Bellare G, et al. (2025) Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(18), e2410718.

Hu W, et al. (2025) High fructose promotes MYCN-amplified neuroblastoma progression through NgBR-ACSS2-mediated biosynthesis of acetyl-CoA. *Cell reports*, 44(7), 115947.